APVO
Aptevo TherapeuticsยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
APVO Profile
Aptevo Therapeutics Inc.
A biotechnology company developing novel immunotherapies for cancer and autoimmune diseases
Biological Technology
--
08/01/2016
NASDAQ Stock Exchange
37
12-31
Common stock
2401 4th Avenue, Suite 1050, Seattle, Washington 98121
--
Aptevo Therapeutics Inc., was incorporated in Delaware in February 2016. The company is a clinical-stage R&D biotechnology company focused on developing novel immunotherapy candidates for the treatment of different forms of cancer. The company has developed two multifunctional platform technologies for the rational design of precision immunomodulatory drugs. The Company's main clinical candidates APVO436 and ALG.APV-527 and preclinical candidates APVO603 and APVO711 were developed using the ADAPTIR modular protein technology platform. The company's preclinical drug candidate APVO 442 was developed using the ADAPTIR-FLEX modular protein technology platform. The company's ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific and multispecific candidate antibodies that enhance the human immune system against cancer cells.
